All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
Introducing
Now you can personalise
your AML Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
The AML Global Portal were delighted to speak to Catherine Smith, UCSF Medical Center, San Francisco, US, during the European School of Hematology (ESH) Translational Research Conference on AML. We asked Catherine Smith: How will the use of FLT3 inhibitors evolve in the future?
She provided her expert opinion outlining the challenge of resistance development, both on-target and off-target and how the field is currently trying to overcome them with drug combination regimens. She provided arguments for a sequential use of different treatment modalities in order to better address the heterogeneity of AML at diagnosis and relapse.
How will the use of FLT3 inhibitors evolve in the future?
Your opinion matters
Subscribe to get the best content related to AML delivered to your inbox